Taro Pharmaceutical Industries Ltd. (NYSE:TARO – Get Rating) saw an uptick in trading volume on Friday . 71,500 shares changed hands during mid-day trading, an increase of 339% from the previous session’s volume of 16,275 shares.The stock last traded at $29.49 and had previously closed at $28.98.
Wall Street Analysts Forecast Growth
A number of brokerages have recently issued reports on TARO. StockNews.com downgraded Taro Pharmaceutical Industries from a “buy” rating to a “hold” rating in a report on Saturday. HC Wainwright lowered their price target on Taro Pharmaceutical Industries from $54.00 to $35.00 and set a “buy” rating for the company in a research report on Wednesday, January 25th.
Taro Pharmaceutical Industries Stock Performance
The stock has a 50 day simple moving average of $26.12 and a two-hundred day simple moving average of $28.45. The firm has a market cap of $1.11 billion, a PE ratio of 24.17 and a beta of 0.64.
Hedge Funds Weigh In On Taro Pharmaceutical Industries
About Taro Pharmaceutical Industries
Taro Pharmaceutical Industries Ltd. engages in the development, manufacturing and marketing of prescribed and over-the-counter pharmaceutical products in the U.S., Canada and Israel. Its products include semi-solids formulations, such as creams and ointments and other dosage forms such as liquids, capsules and tablets, in the dermatological and topical, cardiovascular, neuropsychiatric and anti-inflammatory therapeutic categories.
- Get a free copy of the StockNews.com research report on Taro Pharmaceutical Industries (TARO)
- MarketBeat Week in Review – 5/15 – 5/19
- Applied Materials: Cracks In The Chip Recovery Or Time To Buy?
- Deere & Company Rallies On Farm Equipment Boom, Bullish Outlook
- How Many Roth IRAs Can You Have?
- Why You Should Consider Buying Nvidia Ahead Of Earnings
Receive News & Ratings for Taro Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Taro Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.